Modulating autophagy: A strategy for cancer theyapy

Chinese Journal of Cancer

Volumn 30, Issue 10, 2011, Pages 655-668

  Li, Jun Lin ^a   Han, Shao Liang ^b   Fan, Xia ^c  

^a Yongzhou Central Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Autophagy; Bcl 2; Chemoresistance; Chemotherapy; Nuclear factor b; P53

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 3 METHYLADENINE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ARSENIC TRIOXIDE; BAFILOMYCIN A1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CERAMIDE; CHLOROQUINE; DASATINIB; DEPSIPEPTIDE; DOPAMINE; EVEROLIMUS; EVODIAMINE; FLUOROURACIL; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHENETHYL ISOTHIOCYANATE; PITAVASTATIN; RAPAMYCIN; RIDAFOROLIMUS; ROMIDEPSIN; SIRAMESINE; TACROLIMUS; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

APOPTOSIS; AUTOLYSOSOME; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL STRUCTURE; COLON CANCER; COLORECTAL CANCER; COMPLEX FORMATION; CYTOPLASM; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GLIOMA; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIPID BILAYER; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEUROBLASTOMA; OVARY CANCER; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054727314     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10185     Document Type: Review

References (143)

1. de Duve C, Pressman BC, Gianetto R, et al. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liv er tissue [J]. Biochem J, 1955,60(4):604-617.
2. Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion [J]. Nature, 2008,451 (7182):1069-1075.
3. Seglen PO, Berg TO, Blankson H, et al. Structural aspects of autophagy [J]. Adv Exp Med Biol, 1996,389:103-111.
4. Takeshige K, Baba M, Tsuboi S, et al. Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction [J]. J Cell Biol, 1992,119(2):301-311.
5. Levine B, Kroemer G. Autophagy in the pathogenesis of disease [J]. Cell, 2008,132(1):27-42.
6. Lu B, Finn OJ. T-cell death and cancer immune tolerance [J]. Cell Death Differ, 2008,15(1):70-79.
7. Fidzianska A, Bilinska ZT, Walczak E, et al. Autophagy in transition from hypertrophic cardiomyopathy to heart failure [J]. J Electron Microsc (Tokyo), 2010,59(2):181-183.
8. Marx J. Autophagy: is it cancer-s friend or foe? [J]. Science, 2006,312(5777):1160-1161.
9. Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease [J]. Biochim Biophys Acta, 2009,1792(1):3-13.
10. Bandyopadhyay U, Cuervo AM. Entering the lysosome through a transient gate by chaperone-m ediated autophagy [J]. Autophagy, 2008,4(8):1101-1103.
11. Uttenweiler A, Schwarz H, Neumann H, et al. The vacuolar transporter chaperone (VTC) complex is required for microautophagy [J]. Mol Biol Cell, 2007,18(1):166-175.
12. Krick R, Muhe Y, Prick T, et al. Piecemeal microautophagy of the nucleus: genetic and morphological traits [J]. Autophagy, 2009,5(2):270-272.
13. Liu JJ, Lin M, Yu JY, et al. Targeting apoptotic and autophagic pathways for cancer therapeutics [J]. Cancer Lett, 2011,300(2): 105-114.
14. Ghayad SE, Cohen PA. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients [J]. Recent Pat Anticancer Drug Discov, 2010,5(1):29-57.
15. Maiuri MC, Tasdemir E, Criollo A, et al. Control of autophagy by oncogenes and tumor suppressor genes [J]. Cell Death Differ, 2009,16(1):87-93.
16. Chan EY, Longatti A, McKnight NC, et al. Kinase-in activated ULK proteins inhibit autophagy via their conserved C-te rminal domains using an Atg13-in dependent mechanism [J]. Mol Cell Biol, 2009,29(1):157-171.
17. Chan EY, Tooze SA. Evolution of Atg1 function and regulation [J]. Autophagy, 2009,5(6):758-765.
18. Ganley IG, Lamdu H, Wang J, et al. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy [J]. J Biol Chem, 2009,284(18):12297-12305.
19. Mercer CA, Kaliappan A, Dennis PB. A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy [J]. Autophagy, 2009,5(5):649-662.
20. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34 [J]. Biochem J, 2008,410(1):1-17.
21. Ichimura Y, Kirisako T, Takao T, et al. A ubiquitin-lik e system mediates protein lipidation [J]. Nature, 2000,408 (6811):488-492.
22. Nakatogawa H, Ichimura Y, Ohsumi Y. Atg8, a ubiquitin-like protein required for autophagosome formation, mediates membrane tethering and hemifusion [J]. Cell, 2007,130(1):165-178.
23. Sun Q, Fan W, Zhong Q. Regulation of Beclin-1 in autophagy [J]. Autophagy, 2009,5(5):713-716.
24. Fukuda M, Itoh T. Direct link between Atg protein and small GTPase Rab: Atg16L functions as a potential Rab33 effector in mammals [J]. Autophagy, 2008,4(6):824-826.
25. Eisenberg-Lerner A, Bialik S, Simon HU, et al. Life and death partners: apoptosis, autophagy and the cross-ta lk between them [J]. Cell Death Differ, 2009,16(7):966-975.
26. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth [J]. Genes Dev, 2009,23(5):537-548.
27. Bursch W, Karwan A, Mayer M, et al. Cell death and autophagy: cytokines, drugs, and nutritional factors [J]. Toxicology, 2008,254(3):147-157.
28. Wang W, Guan KL. AMP-activated protein kinase and cancer [J]. Acta Physiol (Oxf), 2009,196(1):55-63.
29. Ikenoue T, Hong S, Inoki K. Monitoring mammalian target of rapamycin (mTOR) activity [J]. Methods Enzymol, 2009,452: 165-180.
30. Degtyarev M, De Maziere A, Orr C, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to. lysosomotropic agents [J]. J Cell Biol, 2008,183(1):101-116.
31. Shinojima N, Yokoyama T, Kondo Y, et al. Roles of the Akt/ mTOR/p70S6K and ERK1/2 signaling pathways in curcumin- induced autophagy [J]. Autophagy, 2007,3(6):635-637.
32. Ramakrishnan S, Nguyen TM, Subramanian IV, et al. Autophagy and angiogenesis inhibition [J]. Autophagy, 2007,3 (5):512-515.
33. Morselli E, Galluzzi L, Kepp O, et al. Anti- and pro-tu mor functions of autophagy [J]. Biochim Biophys Acta, 2009,1793 (9):1524-1532.
34. Tsuchihara K, Fujii S, Esumi H. Autophagy and cancer: dynamism of the metabolism of tumor cells and tissues [J]. Cancer Lett, 2009,278(2):130-138.
35. Papandreou I, Lim AL, Laderoute K, et al. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L [J]. Cell Death Differ, 2008,15(10): 1572-1581.
36. Mazure NM, Pouyssegur J. Atypical BH3-domains of BNIP3 and BNIP3L lead to autophagy in hypoxia [J]. Autophagy, 2009,5(6):868-869.
37. Tafani M, Schito L, Anwar T, et al. Induction of autophagic cell death by a novel molecule is increased by hypoxia [J]. Autophagy, 2008,4(8):1042-1053.
38. Bellot G, Garcia-M edina R, Gounon P, et al. Hypoxia-in duced autophagy is mediated through hypoxia-in ducible factor induction of BNIP3 and BNIP3L via their BH3 domains [J]. Mol Cell Biol, 2009,29(10):2570-2581.
39. Inoki K, Guan KL. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment [J]. Hum Mol Genet, 2009,18(R1):R94-R100.
40. Takahashi Y, Meyerkord CL, Wang HG. Bif-1/endophilin B1: a candidate for crescent driving force in autophagy [J]. Cell Death Differ, 2009,16(7):947-955.
41. Itakura E, Mizushima N. Atg14 and UVRAG: mutually exclusive subunits of mammalian Beclin-1-PI3K complexes [J]. Autophagy, 2009,5(4):534-536.
42. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by Beclin-1 [J]. Nature, 1999,402(6762):672-676.
43. Karantza-Wadsworth V, White E. Role of autophagy in breast cancer [J]. Autophagy, 2007,3(6):610-613.
44. DiPaola RS, Dvorzhinski D, Thalasila A, et al. Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. [J]. Prostate, 2008,68(16):1743-1752.
45. Shen Y, Li DD, Wang LL, et al. Decreased expression of autophagy-re lated proteins in malignant epithelial ovarian cancer [J]. Autophagy, 2008,4(8):1067-1068.
46. Lee JW, Jeong EG, Soung YH, et al. Decreased expression of tumour suppressor Bax-in teracting factor-1 (Bif-1), a Bax activator, in gastric carcinomas [J]. Pathology, 2006,38 (4): 312-315.
47. Kim SY, Oh YL, Kim KM, et al. Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers [J]. Pathology, 2008,40(6):553-557.
48. Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy [J]. Apoptosis, 2009,14(4):376-391.
49. Kang MR, Kim MS, Oh JE, et al. Frameshift mutations of autophagy-re lated genes ATG2B, ATG5, ATG9B and ATG12 in gastric and colorectal cancers with microsatellite instability [J]. J Pathol, 2009,217(5):702-706.
50. Lee JS, Li Q, Lee JY, et al. FLIP-m ediated autophagy regulation in cell death control [J]. Nat Cell Biol, 2009,11(11): 1355-1362.
51. Pattingre S, Bauvy C, Levade T, et al. Ceramide-in duced autophagy: to junk or to protect cells? [J]. Autophagy, 2009,5 (4):558-560.
52. Bialik S, Kimchi A. Autophagy and tumor suppression: recent advances in understanding the link between autophagic cell death pathways and tumor development. [J]. Adv Exp Med Biol, 2008,615:177-200.
53. Crighton D, Wilkinson S, Ryan KM. DRAM links autophagy to p53 and programmed cell death [J]. Autophagy, 2007,3 (1): 72-74.
54. Tasdemir E, Maiuri MC, Galluzzi L, et al. Regulation of autophagy by cytoplasmic p53 [J]. Nat Cell Biol, 2008,10(6): 676-687.
55. Tasdemir E, Chiara Maiuri M, Morselli E, et al. A dual role of p53 in the control of autophagy [J]. Autophagy, 2008,4 (6): 810-814.
56. O'Prey J, Skommer J, Wilkinson S, et al. Analysis of DRAM-related proteins reveals evolutionarily conserved and divergent roles in the control of autophagy. [J]. Cell Cycle, 2009,8(14): 2260-2265.
57. Karin M. Nuclear factor-k appaB in cancer development and progression [J]. Nature, 2006,441(7092):431-436.
58. Wong ET, Tergaonkar V. Roles of NF-k appaB in health and disease: mechanisms and therapeutic potential [J]. Clin Sci (Lond), 2009,116(6):451-465.
59. Djavaheri-Mergny M, Amelotti M, Mathieu J, et al. NF-k appaB activation represses tumor necrosis factor-alpha-in duced autophagy [J]. J Biol Chem, 2006,281(41):30373-30382.
60. Lee DF, Kuo HP, Chen CT, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway [J]. Cell, 2007,130(3):440-455.
61. Dan HC, Baldwin AS. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-in duced mammalian target of rapamycin activation determined by Akt [J]. J Immunol, 2008,180(11):7582-7589.
62. Copetti T, Bertoli C, Dalla E, et al. p65/RelA modulates BECN1 transcription and autophagy [J]. Mol Cell Biol, 2009,29 (10): 2594-2608.
63. O-Connor R. A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance [J]. Curr Cancer Drug Targets, 2009,9(3):273-280.
64. Mayur YC, Peters GJ, Prasad VV, et al. Design of new drug molecules to be used in reversing multidrug resistance in cancer cells [J]. Curr Cancer Drug Targets, 2009,9 (3):298-306.
65. Carew JS, Medina EC, Esquivel JA 2nd, et al. Autophagy inhibition enhances vorinostat-in duced apoptosis via ubiquitinated protein accumulation [J]. J Cell Mol Med, 2010,14 (10):2448-2459.
66. Ondrouskova E, Soucek K, Horvath V, et al. Alternative pathways of programmed cell death are activated in cells with defective caspase-dependent apoptosis [J]. Leuk Res, 2008,32 (4):599-609.
67. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer [J]. Annu Rev Med, 2009,60:207-219.
68. Li J, Hou N, Faried A, et al. Inhibition of autophagy by 3-M A enhances the effect of 5-FU induced apoptosis in colon cancer cells [J]. Ann Surg Oncol, 2009,16(3):761-771.
69. Sasaki K, Tsuno NH, Sunami E, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells [J]. BMC Cancer, 2010,10: 370.
70. O-Donovan TR, O-Sullivan GC, McKenna S. Induction of autophagy by drug-re sistant esophageal cancer cells promotes their. survival and recovery following treatment with chemotherapeutics [J]. Autophagy, 2011,7(6):509-524.
71. Torguson R, R Waksman. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Xience V Everolimus-Eluting Coronary Stent. [J]. Am J Cardiol, 2008,102(12):1624-1630.
72. Wu YT, Tan HL, Huang Q, et al. Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via. suppression of autophagy [J]. Autophagy, 2009,5(6):824-834.
73. Chiu HW, Ho SY, Guo HR, et al. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-M G cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. [J]. Autophagy, 2009,5(4):472-483.
74. Yang YP, Liang ZQ, Gao B, et al. Dynamic effects of autophagy on arsenic trioxide-in duced death of human leukemia cell line HL60 cells [J]. Acta Pharmacol Sin, 2008,29 (1):123-134.
75. Charoensuk V, Gati WP, Weinfeld M, et al. Differential cytotoxic effects of arsenic compounds in human acute promyelocytic. leukemia cells [J]. Toxicol Appl Pharmacol, 2009,239(1):64-70.
76. Zustovich F, Lombardi G, Della Puppa A, et al. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-re fractory high-grade malignant glioma [J]. Anticancer Res, 2009,29(10):4275-4279.
77. Pirtoli L, Cevenini G, Tini P, et al. The prognostic role of Beclin-1 protein expression in high-grade gliomas [J]. Autophagy, 2009,5(7):930-936.
78. Addeo R, De Rosa C, Faiola V, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases [J]. Cancer, 2008,113 (9):2524-2531.
79. Nguyen TM, Subramanian IV, Kelekar A, et al. Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells [J]. Blood, 2007,109(11):4793-4802.
80. Bommareddy A, Hahm ER, Xiao D, et al. Atg5 regulates phenethyl isothiocyanate-in duced autophagic and apoptotic cell death in human prostate cancer cells [J]. Cancer Res, 2009,69 (8):3704-3712.
81. Gao M, Yeh PY, Lu YS, et al. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-re lated autophagy in hepatocellular carcinoma. [J]. Cancer Res, 2008,68 (22): 9348-9357.
82. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, et al. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb) [J]. Clin Transl Oncol, 2009,11(7):455-459.
83. Liu TJ, Koul D, LaFortune T, et al. NVP-B EZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas [J]. Mol Cancer Ther, 2009,8(8):2204-2210.
84. Yuk JM, Shin DM, Song KS, et al. Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy [J]. Autophagy, 2010,6(1):46-60.
85. Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, et al. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance [J]. Autophagy, 2009,5(3):400-403.
86. Wu WK, Cho CH, Lee CW, et al. Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells. [J]. Autophagy, 2010,6(2):228-238.
87. Malizzia LJ, Hsu A. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma [J]. Clin J Oncol Nurs, 2008,12(4):639-646.
88. Hudes GR. Targeting mTOR in renal cell carcinoma [J]. Cancer, 2009,115(10 Suppl):2313-2320.
89. Konings IR, Verweij J, Wiemer EA, et al. The applicability of mTOR inhibition in solid tumors [J]. Curr Cancer Drug Targets, 2009,9(3):439-450.
90. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies [J]. Leuk Lymphoma, 2009,50 (12):1916-1930.
91. Wysocki PJ. MTOR in renal cell cancer: modulator of tumor biology and therapeutic target [J]. Expert Rev Mol Diagn, 2009,9(3):231-241.
92. Hess G, Smith SM, Berkenblit A, et al. Temsirolimus in mantle cell lymphoma and other non-H odgkin lymphoma subtypes [J]. Semin Oncol, 2009,36 (Suppl 3):S37-S45.
93. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials [J]. Semin Oncol, 2009,36(Suppl 3):S46-S58.
94. Lefranc F, Rynkowski M, DeWitte O, et al. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment [J]. Adv Tech Stand Neurosurg, 2009,34:3-35.
95. Sanchez-M unoz A, Perez-Ruiz E, Jimenez B, et al. Targeted therapy of metastatic breast cancer [J]. Clin Transl Oncol, 2009,11(10):643-650.
96. Qian W, Liu J, Jin J, et al. Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-re gulation of Beclin-1 [J]. Leuk Res, 2007,31(3):329-339.
97. Kanzawa T, Zhang L, Xiao L, et al. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. [J]. Oncogene, 2005,24(6):980-991.
98. Kanzawa T, Kondo Y, Ito H, et al. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide [J]. Cancer Res, 2003,63(9):2103-2108.
99. Xu SN, Chen JP, Liu JP, et al. Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta- analysis [J]. Zhong Xi Yi Jie He Xue Bao, 2009,7 (9):801-808. [in Chinese]
100. Chen X, Zhang M, Liu LX. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells [J]. Oncol Rep, 2009,22(1):73-80.
101. Quick A, Patel D, Hadziahmetovic M, et al. Current therapeutic paradigms in glioblastoma [J]. Rev Recent Clin Trials, 2010,5 (1):14-27.
102. Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-re sistant cancers, with a special emphasis on glioblastomas [J]. Oncologist, 2007,12(12):1395-403.
103. Fu J, Liu ZG, Liu XM, et al., Glioblastoma stem cells resistant to temozolomide-in duced autophagy [J]. Chin Med J (Engl), 2009,122(11):1255-1259.
104. Gao S, Yang XJ, Zhang WG, et al. Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-M G glioma cells in vitro [J]. Chin Med J (Engl), 2009,122(11):1260-1266.
105. Tyler MA, Ulasov IV, Lesniak MS. Cancer cell death by design: apoptosis, autophagy and glioma virotherapy [J]. Autophagy, 2009,5(6):856-857.
106. Yokoyama T, Iwado E, Kondo Y, et al. Autophagy-in ducing agents augment the antitumor effect of telerase-s elve oncolytic adenovirus OBP-405 on glioblastoma cells [J]. Gene Ther, 2008,15(17):1233-1239.
107. Ulasov IV, Sonabend AM, Nandi S, et al. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo [J]. Br J Cancer, 2009,100(7):1154-1164.
108. Milano V, Piao Y, LaFortune T, et al. Dasatinib-in duced autophagy is enhanced in combination with temozolomide in glioma [J]. Mol Cancer Ther, 2009,8(2):394-406.
109. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-H ernandez A, et al. Energy metabolism in tumor cells [J]. FEBS J, 2007,274 (6):1393-1418.
110. Wu YC, Wu WK, Li Y, et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells [J]. Biochem Biophys Res Commun, 2009,382(2):451-456.
111. Samaddar JS, Gaddy VT, Duplantier J, et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance [J]. Mol Cancer Ther, 2008,7(9):2977-2987.
112. Pattingre S, Bauvy C, Carpentier S, et al. Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-in duced macroautophagy [J]. J Biol Chem, 2009,284(5):2719-2728.
113. Wessely R, Kastrati A, Mehilli J, et al. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design [J]. Eur Heart J, 2007,28(22):2720-2725.
114. Satyan KS, Swamy N, Dizon DS., et al. Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation [J]. Gynecol Oncol, 2006,103(1):261-270.
115. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-re sistant malignant glioma [J]. J Clin Oncol, 2009,27(8):1262-1267.
116. Gomez-Santos C, Ferrer I, Santidrian AF, et al. Dopamine induces autophagic cell death and alpha-s ynuclein increase in human neuroblastoma SH-SY5Y cells [J]. J Neurosci Res, 2003,73(3):341-350.
117. Park MA, Curiel DT, Koumenis C, et al. PERK-dependent regulation of HSP70 expression and the regulation of autophagy [J]. Autophagy, 2008,4(3):364-367.
118. Chapman JV, Gouaze-Anderson V, Messner MC, et al. Metabolism of short-chain ceramide by human cancer cells implications for therapeutic approaches [J]. Biechem Pharmacol, 2010,80(3):308-315.
119. de Medina P, Silvente-Poirot S, Poirot M. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation [J]. Autophagy, 2009,5(7):1066-1067.
120. Xiong HY, Guo XL, Bu XX, et al. Autophagic cell death induced by 5-FU in Bax or PUMA deficient human colon cancer cell [J]. Cancer Lett, 2010,288(1):68-74.
121. Kim RH, Bold RJ, Kung HJ. ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer [J]. Autophagy, 2009,5(4):567-568.
122. Wu WK, Wu YC, Yu L, et al. Induction of autophagy by proteasome inhibitor is associated with proliferative arrest in colon cancer cells [J]. Biochem Biophys Res Commun, 2008,374(2):258-263.
123. Watanabe M, Adachi S, Matsubara H, et al. Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation [J]. Int J Cancer, 2009,124(1): 55-67.
124. Yamaguchi J, Sasaki M, Sato Y, et al. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma [J]. Cancer Sci, 2010,101 (2):355-362.
125. Tsuboi Y, Kurimoto M, Nagai S, et al. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-k appa B activation in human glioma cell lines [J]. J Neurosurg, 2009,110(3):594-604.
126. Shingu T, Fujiwara K, Bogler O, et al. Stage-s pecific effect of inhibition of autophagy on chemotherapy-in duced cytotoxicity [J]. Autophagy, 2009,5(4):537-539.
127. Shingu T, Fujiwara K, Bogler O, et al. Inhibition of autophagy at a late stage enhances imatinib-in duced cytotoxicity in human malignant glioma cells [J]. Int J Cancer, 2009,124 (5):1060-1071.
128. Ertmer A, Huber V, Gilch S, et al. The anticancer drug imatinib induces cellular autophagy [J]. Leukemia, 2007,21(5):936-942.
129. Yang J, Wu LJ, Tashino S, et al. Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells [J]. Free Radic Res, 2008,42(5):492-504.
130. Signorelli P, Munoz-Olaya JM, Gagliostro V, et al. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells [J]. Cancer Lett, 2009,282(2):238-243.
131. Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity [J]. Antioxid Redox Signal, 2009,11 (11): 2851-2897.
132. Ohshiro K, Rayala SK, Kondo S, et al. Identifying the estrogen receptor coactivator PELP1 in autophagosomes [J]. Cancer Res, 2007,67(17):8164-8171.
133. Matrone A, Grossi V, Chiacchiera F, et al. p38alpha is required for ovarian cancer cell metabolism and survival [J]. Int J Gynecol Cancer, 2010,20(2):203-211.
134. Comes F, Matrone A, Lastella P, et al. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells [J]. Cell Death Differ, 2007,14 (4):693-702.
135. Chiacchiera F, Matrone A, Ferrari E, et al. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription [J]. Cell Death Differ, 2009,16(9):1203-1214.
136. Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, et al. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine [J]. Cancer Res, 2007,67(5):2217-2225.
137. Ostenfeld MS, Hoyer-Hansen M, Bastholm L, et al. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation [J]. Autophagy, 2008,4(4):487-499.
138. Alonso MM, Gomez-Manzano C, Bekele BN, et al. Adenovirus- based strategies overcome temozolomide resistance by silencing the O6-m ethylguanine-DNA methyltransferase promoter [J]. Cancer Res, 2007,67(24):11499-11504.
139. Ryu SY, Kim K, Lee WS, et al. Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines [J]. J Gynecol Oncol, 2009,20(1): 48-54.
140. Chen N, Karantza V. Autophagy as a therapeutic target in cancer [J]. Cancer Biol Ther. 2011,11(2):157-168.
141. Roy S, Debnath J. Autophagy and tumorigenesis [J]. Semin Immunopathol, 2010,32(4):383-396.
142. Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-x L play important roles in the crosstalk between autophagy and apoptosis [J]. FEBS J, 2011,278(3):403-413.
143. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer [J]. Cell, 2009,137(6):1001-1004.